Edesa Biotech (EDSA) Stock Price, News & Analysis

Company Overview

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory and immune-mediated diseases. The company does not have any marketed products and concentrates on advancing investigational treatments through clinical development and regulatory evaluation.

Edesa’s lead program has been EB01, a topical therapy being developed for chronic hand eczema, a painful inflammatory skin condition that can significantly affect patients’ daily activities. The company has also evaluated EB05, an antibody-based treatment candidate intended to address excessive inflammation associated with acute respiratory distress syndrome and other serious conditions. The status of individual programs may change as clinical and regulatory work progresses.

Edesa is headquartered in Markham, Ontario, Canada, and has conducted development activities in Canada and the United States. The company was founded to pursue therapies for diseases with limited treatment options and has worked with research, clinical, and regulatory partners in advancing its programs. Par Nijhawan has served as the company’s chief executive officer.

Key Stats

• Today's Range: $3.49 to $3.76
• 50-Day Range: $3.51 to $5.75
• 52-Week Range: $0.72 to $20.32
• Volume: 36,199 shs
• Average Volume: 38,998 shs
• Market Capitalization: $33.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Edesa Biotech Stock Analysis - MarketRank™

Edesa Biotech scored higher than 59% of companies evaluated by MarketBeat, and ranked 390th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Edesa Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Edesa Biotech has a consensus price target of $5.00, representing about 42.5% upside from its current price of $3.51.

Amount of Analyst Coverage

Edesa Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Edesa Biotech are expected to grow in the coming year, from ($1.99) to ($1.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edesa Biotech is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edesa Biotech is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Edesa Biotech has a P/B Ratio of 7.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.79% of the float of Edesa Biotech has been sold short.

Short Interest Ratio / Days to Cover

Edesa Biotech has a short interest ratio ("days to cover") of 4.81.

Change versus previous month

Short interest in Edesa Biotech has recently decreased by 6.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edesa Biotech does not currently pay a dividend.

Dividend Growth

Edesa Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Edesa Biotech has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Edesa Biotech this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for EDSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Edesa Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.40% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

5.50% of the stock of Edesa Biotech is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 12/11/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EDSA
• CIK: 1540159
• Web: www.edesabiotech.com
• Phone: (905) 475-1234
• Fax: 805-488-2889
• Employees: 17
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Edesa Biotech: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +42.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -560.22%
• Return on Assets: -105.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.76
• Quick Ratio: 2.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 7.80

Miscellaneous

• Outstanding Shares: 9,640,000
• Free Float: 7,289,000
• Market Cap: $33.84 million
• Optionable: Not Optionable
• Beta: 1.20